Fosaprepitant
Clinical data | |
---|---|
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a604003 |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | >95% (aprepitant) |
Metabolism | To aprepitant |
Elimination half-life | 9 to 13 hours (aprepitant) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H22F7N4O6P |
Molar mass | 614.406 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.
Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2]
See also
References
- ^ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
- ^ "European Public Assessment Report for Ivemend (from the EMEA website)". Archived from the original on 2008-02-28. Retrieved 2008-03-15.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help)